Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant 5-FU and Radiotherapy in Resected Pancreatic Cancer
NCT00010062Phase 2Unknown
- Sponsor
- GERCOR
- Start
- Oct 2000
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by GERCOR. Primary endpoint: Tolerance of adjuvant fluorouracil with concurrent radiotherapy. Status: unknown.
02
Drugs
fluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00010062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010062.